Market capitalization | $81.91m |
Enterprise Value | $108.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 14.06 |
P/S ratio (TTM) P/S ratio | 10.64 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 248.39% |
Revenue (TTM) Revenue | $7.70m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Clearside Biomedical, Inc. forecast:
7 Analysts have issued a Clearside Biomedical, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 7.70 7.70 |
248%
248%
|
|
Gross Profit | 7.54 7.54 |
377%
377%
|
|
EBITDA | -24 -24 |
18%
18%
|
EBIT (Operating Income) EBIT | -25 -25 |
18%
18%
|
Net Profit | -32 -32 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Head office | United States |
CEO | George Lasezkay |
Employees | 30 |
Founded | 2011 |
Website | www.clearsidebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.